Dr. Reddy's Laboratories Limited (RDDA) - Total Liabilities
Based on the latest financial reports, Dr. Reddy's Laboratories Limited (RDDA) has total liabilities worth €179.92 Billion EUR (≈ $210.35 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore RDDA cash generation efficiency to assess how effectively this company generates cash.
Dr. Reddy's Laboratories Limited - Total Liabilities Trend (2017–2025)
This chart illustrates how Dr. Reddy's Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Dr. Reddy's Laboratories Limited to evaluate the company's liquid asset resilience ratio.
Dr. Reddy's Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Dr. Reddy's Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Max Healthcare Institute Limited
NSE:MAXHEALTH
|
India | Rs62.29 Billion |
|
Equatorial Energia S.A
SA:EQTL3
|
Brazil | R$93.37 Billion |
|
Grupo Aeroportuario del Pacífico S.A.B. de C.V
F:G9N
|
Germany | €59.56 Billion |
|
SPX Corp
NYSE:SPXC
|
USA | $1.37 Billion |
|
United Spirits Limited
NSE:MCDOWELL-N
|
India | Rs50.76 Billion |
|
Sichuan Road & Bridge Group Co Ltd
SHG:600039
|
China | CN¥202.34 Billion |
|
BAWAG Group AG
VI:BG
|
Austria | €68.05 Billion |
|
Strabag SE
VI:STR
|
Austria | €10.06 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Dr. Reddy's Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Dr. Reddy's Laboratories Limited stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dr. Reddy's Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dr. Reddy's Laboratories Limited (2017–2025)
The table below shows the annual total liabilities of Dr. Reddy's Laboratories Limited from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €155.82 Billion ≈ $182.17 Billion |
+45.67% |
| 2024-03-31 | €106.97 Billion ≈ $125.06 Billion |
+18.87% |
| 2023-03-31 | €89.99 Billion ≈ $105.21 Billion |
-15.21% |
| 2022-03-31 | €106.13 Billion ≈ $124.07 Billion |
+17.25% |
| 2021-03-31 | €90.51 Billion ≈ $105.82 Billion |
+17.16% |
| 2020-03-31 | €77.25 Billion ≈ $90.32 Billion |
-9.36% |
| 2019-03-31 | €85.23 Billion ≈ $99.64 Billion |
-14.03% |
| 2018-03-31 | €99.14 Billion ≈ $115.91 Billion |
+3.52% |
| 2017-03-31 | €95.78 Billion ≈ $111.97 Billion |
-- |
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more